Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACHROMYCIN vs OFIRMEV
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-t RNA from binding to the A site.
OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.
Infections caused by susceptible strains of bacteria (e.g., Mycoplasma pneumoniae, Chlamydia trachomatis, Rickettsia species),Acne vulgaris,Periodontitis (as adjunctive therapy),Off-label: Chronic obstructive pulmonary disease exacerbations, malaria prophylaxis
Management of mild to moderate pain,Management of moderate to severe pain with adjunctive opioid analgesics,Reduction of fever
250-500 mg orally every 6 hours or 500 mg intravenously every 12 hours.
IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.
6-12 hours; prolonged to 48-72 hours in severe renal impairment
Terminal elimination half-life is 2-3 hours in adults (2.5-3 hours in children). Clinically, dosing every 4-6 hours is needed to maintain therapeutic levels.
Primarily renally excreted unchanged; minimal hepatic metabolism.
Acetaminophen is primarily metabolized in the liver via conjugation with glucuronide (50-60%) and sulfate (20-30%). A minor amount is oxidized by cytochrome P450 (CYP2E1, CYP1A2, CYP3A4) to a toxic reactive metabolite (NAPQI), which is normally detoxified by glutathione. At toxic doses, glutathione is depleted, leading to NAPQI accumulation and hepatotoxicity.
Renal (60-80% unchanged via glomerular filtration); biliary/fecal (10-20%)
Primarily renal (85% as sulfate and glucuronide conjugates, 10% as unchanged drug). Less than 5% fecal/biliary.
50-60% bound to serum proteins
10-25% bound to albumin at therapeutic concentrations.
1.5-2.0 L/kg; indicates extensive tissue penetration
0.8-1.0 L/kg. Indicates distribution into total body water.
Oral: 75-80%; Topical: minimal systemic absorption
100% (intravenous); not applicable for other routes as OFIRMEV is IV only.
GFR 50-80 m L/min: no adjustment; GFR 10-50 m L/min: administer every 12-24 hours; GFR <10 m L/min: administer every 24 hours or avoid.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, extend dosing interval to every 8 hours; maximum daily dose 3000 mg.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce total daily dose by 50% (max 2000 mg/day). Child-Pugh Class C: Contraindicated or use with extreme caution; reduce dose to 50% of standard and extend interval to every 8 hours; maximum 2000 mg/day.
25-50 mg/kg/day orally divided every 6 hours; maximum 2 g/day.
Weight-based: <10 kg: 7.5 mg/kg/dose every 6 hours; 10-50 kg: 15 mg/kg/dose every 6 hours; >50 kg: 1000 mg every 6 hours or 650 mg every 4 hours. Maximum single dose: 15 mg/kg (up to 1000 mg); maximum daily dose: 75 mg/kg (up to 4000 mg).
Initiate at lower end of dosing range due to age-related renal function decline; monitor renal function.
No specific dose adjustment; consider reduced renal function. For Cr Cl <30 m L/min, extend interval to every 8 hours. Maximum daily dose: 3000 mg in frail elderly or with comorbidities.
No FDA boxed warning
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.
Photosensitivity reactions,Esophageal ulceration if taken with insufficient fluids,Pseudotumor cerebri in adults,Pancreatitis,Hepatotoxicity,Renal impairment (accumulation may worsen renal function),Superinfection with resistant organisms
Risk of serious hepatotoxicity, especially with doses >4000 mg/day or in patients with underlying liver disease,Risk of severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis) – discontinue at first sign of rash,Risk of hypersensitivity reactions including anaphylaxis,Use caution in patients with severe hepatic impairment, active hepatic disease, or alcoholism,Avoid concurrent use of other acetaminophen-containing products
Hypersensitivity to tetracyclines,Pregnancy (second and third trimesters) due to fetal harm,Children under 8 years due to permanent tooth discoloration and enamel hypoplasia,Severe hepatic or renal impairment
Known hypersensitivity to acetaminophen or any component of the formulation,Severe hepatic impairment or active liver disease (relative contraindication without black box)
Avoid dairy products (milk, cheese, yogurt) within 2-3 hours of taking Achromycin, as calcium binds tetracycline and reduces absorption. Also avoid iron-fortified foods, calcium-fortified juices, and high-calcium meals. Take on an empty stomach with a full glass of water; food, especially dairy, decreases absorption by up to 50%.
No known food interactions. However, avoid excessive alcohol consumption as it may increase the risk of liver damage.
ACHROMYCIN (tetracycline) is classified as FDA Pregnancy Category D. First trimester: Associated with minor malformations, but risk is low. Second and third trimesters: Exposure can cause permanent discoloration of deciduous teeth (yellow-gray-brown) due to deposition during calcification, and reversible inhibition of bone growth. Avoid use after the fourth month of pregnancy. Risk of maternal hepatotoxicity if used intravenously in pregnancy.
Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dose use in third trimester may be associated with preterm birth or low birth weight. Avoid prolonged use above recommended doses.
Tetracycline is excreted into breast milk in low concentrations. Theoretical risk of dental discoloration and bone growth suppression in nursing infants, but levels are usually below therapeutic. M/P ratio is approximately 0.5-0.8. Use with caution, especially in infants with prolonged exposure. American Academy of Pediatrics considers tetracyclines compatible with breastfeeding.
Acetaminophen is excreted in breast milk in low concentrations (M/P ratio approximately 0.9-1.0). Considered compatible with breastfeeding; peak milk levels occur 1-2 hours after maternal dosing. Use lowest effective dose for shortest duration.
No dosage adjustment is recommended for pregnancy; however, use is contraindicated after the first trimester due to risks to the fetus. If essential, use the lowest effective dose for the shortest duration. Intravenous doses should be cautious due to risk of hepatotoxicity; reduce dose in renal impairment.
No dose adjustment required during pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may lead to lower peak concentrations but standard dosing remains effective. Maximum single dose: 1 g; maximum daily dose: 4 g.
Achromycin (tetracycline) should be administered on an empty stomach (1 hour before or 2 hours after meals) to ensure adequate absorption. Avoid concurrent use with dairy products, antacids, iron, calcium, magnesium, or bismuth subsalicylate as they chelate tetracycline and reduce absorption. Tetracycline can cause photosensitivity; advise patients to avoid prolonged sun exposure and use sunscreen. It is contraindicated in pregnancy (risk of hepatotoxicity and fetal bone/teeth discoloration), lactation, and children under 8 years (permanent tooth discoloration and bone growth inhibition). Monitor for signs of superinfection, especially Clostridium difficile-associated diarrhea. Tetracycline may increase the effect of warfarin; monitor INR closely.
OFIRMEV (acetaminophen) injection is an IV formulation of acetaminophen used for pain and fever management. It is a prodrug that requires no hepatic conversion, providing rapid onset of action. Monitor for hepatotoxicity; maximum daily dose is 4 grams in adults but lower in patients with hepatic impairment or malnutrition. Do not exceed 1 gram per dose. Hypotension and anaphylaxis have been reported. Not interchangeable with oral acetaminophen due to dose equivalency. Use with caution in patients with alcohol use disorder.
Take this medication on an empty stomach, at least 1 hour before or 2 hours after meals.,Do not take with dairy products, antacids, iron supplements, or calcium supplements; separate by at least 2-3 hours.,Avoid excessive sunlight or tanning beds; use sunscreen and wear protective clothing to prevent severe sunburn.,Complete the full course of treatment even if you feel better; do not skip doses.,Notify your doctor immediately if you develop watery or bloody diarrhea, rash, headache, blurred vision, or signs of infection worsening.,Do not use if you are pregnant, planning to become pregnant, or breastfeeding; this medication can harm the unborn baby or nursing infant.,Keep out of reach of children; expired tetracycline can cause kidney damage.
OFIRMEV is given intravenously for pain or fever.,Do not take additional acetaminophen-containing medications while receiving OFIRMEV.,Report any signs of allergic reaction (rash, itching, swelling, trouble breathing).,Seek immediate medical attention if you experience severe abdominal pain, yellowing of skin or eyes, or dark urine.,Inform your healthcare provider about all medications you are taking, especially blood thinners.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACHROMYCIN vs OFIRMEV, answered by our medical review team.
ACHROMYCIN is a Tetracycline Antibiotic that works by Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-t RNA from binding to the A site.. OFIRMEV is a Non-opioid Analgesic that works by OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACHROMYCIN and OFIRMEV depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACHROMYCIN is: 250-500 mg orally every 6 hours or 500 mg intravenously every 12 hours.. The standard adult dose of OFIRMEV is: IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACHROMYCIN and OFIRMEV in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACHROMYCIN is classified as Category C. ACHROMYCIN (tetracycline) is classified as FDA Pregnancy Category D. First trimester: Associated with minor malformations, but risk is low. Second and third trimesters: Exposure ca. OFIRMEV is classified as Category C. Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dos. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.